Skip to main content
. 2018 Apr 9;9(5):422–427. doi: 10.1021/acsmedchemlett.7b00510

Figure 3.

Figure 3

(a) Western blot of ERK1/2 and p-ERK1/2 after treatment with compounds 53 and 56 for 15 min at concentrations of 100 nM, 1 μM respectively. (b) Western blot of ERK1/2 and p-ERK1/2 after treatment with the known GPR35 agonist Zaprinast (Zap) at 1 μM and Western blot of ERK1/2 and p-ERK1/2 after treatment with compounds for 10 min at the same concentrations as in (a) in the presence of ML-145 (25 μM) for 5 min.